VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology.

The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine.

It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system.

Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial.

The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.

In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies.

It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome.

VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants.

The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016.

VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.